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Abstract
Background: Functional analysis of mononuclear leukocytes in the female genital mucosa is essential for understanding the
immunologic effects of HIV vaccines and microbicides at the site of HIV exposure. However, the best female genital tract
sampling technique is unclear.
Methods and Findings: We enrolled women from four sites in Africa and the US to compare three genital leukocyte
sampling methods: cervicovaginal lavages (CVL), endocervical cytobrushes, and ectocervical biopsies. Absolute yields of
mononuclear leukocyte subpopulations were determined by flow cytometric bead-based cell counting. Of the non-invasive
sampling types, two combined sequential cytobrushes yielded significantly more viable mononuclear leukocytes than a CVL
(p,0.0001). In a subsequent comparison, two cytobrushes yielded as many leukocytes (,10,000) as one biopsy, with
macrophages/monocytes being more prominent in cytobrushes and T lymphocytes in biopsies. Sample yields were
consistent between sites. In a subgroup analysis, we observed significant reproducibility between replicate same-day
biopsies (r = 0.89, p = 0.0123). Visible red blood cells in cytobrushes increased leukocyte yields more than three-fold
(p = 0.0078), but did not change their subpopulation profile, indicating that these leukocytes were still largely derived from
the mucosa and not peripheral blood. We also confirmed that many CD4+ T cells in the female genital tract express the a4b7
integrin, an HIV envelope-binding mucosal homing receptor.
Conclusions: CVL sampling recovered the lowest number of viable mononuclear leukocytes. Two cervical cytobrushes
yielded comparable total numbers of viable leukocytes to one biopsy, but cytobrushes and biopsies were biased toward
macrophages and T lymphocytes, respectively. Our study also established the feasibility of obtaining consistent flow
cytometric analyses of isolated genital cells from four study sites in the US and Africa. These data represent an important
step towards implementing mucosal cell sampling in international clinical trials of HIV prevention.
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Introduction
Most HIV transmission occurs across a mucosal surface,
especially across the mucosa of the female genital tract (FGT)
[1]. In order for vaccines to prevent infection, local immunity in
the cervical and vaginal mucosa is likely to be necessary. Several
large HIV vaccine trials carried out in the recent past indicated
that anti-HIV immune responses measured in peripheral blood
may not be good surrogates of the protective efficacy elicited at
mucosal sites. The HIV vaccines tested in the Step, Phambili and
HVTN 505 trials failed despite stimulating strong cellular anti-
HIV immune responses in peripheral blood [2–4], while the
vaccine in the RV144 trial was marginally protective despite
eliciting much weaker peripheral blood responses [5,6]. These
discrepant clinical outcomes could likely be explained by the
nature of the immune responses at mucosal sites. However,
mucosal sampling to assess cellular responses was not performed in
these trials, mostly due to logistical challenges and a lack of
knowledge about ideal sample types and processing procedures.
In addition to its importance for vaccine studies, mucosal
sampling is highly relevant in microbicide trials to understand how
microbicides affect the mucosa [7–9] and to perform pharmaco-
dynamic studies, such as determining ex vivo HIV infectivity of
tissue from trial participants as a surrogate of product efficacy
[10,11]. Furthermore, mucosal sampling is integral to studies of
the basic immunobiology of the FGT and of other sexually
transmitted infections. Diverse methods exist for sampling cells
from the FGT, including most prominently cervicovaginal lavage
(CVL), endocervical cytobrushes and ectocervical biopsies. The
relative cellular yield from these procedures is unclear, as are any
differences in the leukocyte subpopulations obtained from each
procedure. Here we address the question of optimal mucosal
sample type in an international, multisite collaboration. We find
that CVL is unsuitable for cellular analysis, while two sequential
cervical cytobrushes give a similar number of leukocytes (about
10,000 cells) to one biopsy, though the subpopulation profiles of
the isolated cells differ. Our results provide guidance for mucosal
cell sampling, processing, and flow cytometric analyses in HIV
prevention trials.
Methods
Participant characteristics and study sites
Four research sites participated in the study: Chicago, USA;
Nairobi, Kenya; Cape Town, South Africa; and Seattle, USA. The
Institutional Review Boards at each site approved the study
(University of Illinois at Chicago, Kenyatta National Hospital,
University of Cape Town, University of Washington). All main
study participants gave informed written consent prior to
enrollment. Women between ages 18 and 55 were eligible for
the study if they were HIV uninfected, tested negative for
gonorrhea, chlamydia, and trichomonas at the sampling visit, and
reported at least six normal menstrual cycles within the past year
(except in South Africa where a number of women using the
hormone contraceptive depot medroxyprogesterone acetate
[DMPA] were amenorrheic). At the time of each study visit,
blood was obtained for HIV testing by ELISA, first-catch urine for
gonorrhea and chlamydia testing by nucleic acid amplification,
and vaginal swabs from the posterior fornix for Trichomonas
testing by InpouchTM culture (BioMed Diagnostics, White City,
OR, USA) and for Gram staining to diagnose bacterial vaginosis
(BV) by Nugent scoring. Gram stains with a Nugent score $7 or a
Nugent score of 4–6 and the presence of clue cells were classified
as signifying BV. BV was not an exclusion criterion. Hormonal
contraception use differed between participants and sites, as
described in the Results.
At the Seattle site, discarded vaginal tissues from vaginal repair
surgeries were used for optimization of the biopsy processing
method and development of the a4b7 staining protocol. These
tissues were obtained anonymously under a waiver of consent
approved by the IRBs of the University of Washington and the
Fred Hutchinson Cancer Research Center.
Sample collection and transport
Samples were collected between 16–24 days from start of the
previous menstrual cycle (first day of menstruation), which is
considered to be a window of vulnerability for HIV infection
[12,13]. All samples were transported to the laboratories on wet
ice and processed within four hours of collection.
In Part 1 of the study, we compared the immune cells obtained
by endocervical cytobrush and CVL at three study sites, Chicago,
Nairobi and Seattle. Different sites for this part of the study used
different cytobrush samplers according to their standard collection
method. Chicago used Cytobrush Plus GT cell collectors
(CooperSurgical, Trumbull, CT, USA), Nairobi used Bio Nuclear
Diagnostics CYT-003A Endocervical cytobrushes, and Seattle
used Cytobrush Plus cell collectors (CooperSurgical). Samples
were obtained in the following order: diagnostic samples for STI
testing, CVL, and cytobrush. CVL was obtained by placing 10 mL
of phosphate-buffered saline on the cervix and collecting the fluid
from the posterior fornix. Collected fluid was placed in a 15 mL
conical tube. For the cytobrush samples, mucus was wiped from
the cervix, the cytobrush was gently inserted into the cervical os,
rotated 360u, removed, and placed into 5 mL RPMI-1640. A
second cytobrush immediately followed. Any visible blood
contamination was noted.
In Part 2 of the study, we compared endocervical cytobrush and
ectocervical biopsy sampling at three study sites, Chicago, Nairobi
and Seattle. In this part of the study, all sites used Digene Cervical
Sampler cytobrushes (Qiagen, Valencia, CA, USA). Sampling for
Part 2 occurred in the following order: diagnostic samples for STI
testing, cytobrush, and biopsy. Cytobrushes were collected as
above. One biopsy was taken from the upper left quadrant of the
ectocervix using a Baby Tischler Biopsy Forceps (Wallach
Surgical, Trumbull, CT, USA) with a 4.262.3 mm bite size. A
second biopsy was taken from the upper right quadrant in a subset
of participants from Nairobi. The biopsy was placed into 5 mL
RPMI-1640. No local injection anesthetic was used before biopsy
collection.
Endocervical cytobrushes were also obtained in Cape Town
from women with or without DMPA contraception, using the
Digene Cervical Sampler cytobrushes. Cape Town did not
perform CVL or biopsy sampling.
Cervicovaginal lavage (CVL) processing
Samples were centrifuged and the pellet transferred into tubes
for flow cytometric staining. The full CVL processing protocol is
included in the File S1.
Endocervical cytobrush processing
The two cytobrushes were processed sequentially and the
extracted cells were combined for staining and flow cytometric
analysis. Cytobrushes were inserted into 25 mL serological
pipettes containing 20 mL room temperature phosphate buffered
saline (PBS). The brush was moved in and out of the tip of the
pipette while the PBS was gradually expelled, extracting the cells
from the cytobrush and washing them through a 100 mm cell
strainer into a 50 mL conical tube (BD, Franklin Lakes, NJ, USA).
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This was repeated with another 10 mL PBS and then the
cytobrushes were scraped on the edge of the cell strainer and
discarded. The 5 mL RPMI-1640 in the transport tube was passed
through the strainer and the tube washed with an additional
15 mL PBS. If the strainer became clogged with mucus, the mucus
was pipetted up and down in the serological pipette and broken
up. After straining, the 50 mL cell suspension was pipetted up and
down several times to break up any remaining mucus. The full
cytobrush processing protocol is included in File S2.
Leukocyte isolation from ectocervical biopsies
To determine the optimal method of leukocyte isolation from
biopsies, three methods were tested on human vaginal tissue:
collagenase digestion, emigration, and enzyme cocktail digestion.
Emigration and collagenase digestion were based on prior
experience in the Seattle laboratory [14,15]. The enzyme cocktail
digestion was based on a protocol used in the laboratory of Dr.
Craig Hendrix in Baltimore [16]. The methods were tested in
parallel, with three replicates each time, on tissue from two
separate donors. The cells were stained with the panel described
below and cell yield and distributions were compared.
Leukocyte isolation by collagenase digestion
R15 and collagenase digestion media were prepared fresh
before each biopsy digestion. R15 consisted of RPMI-1640,
penicillin-streptomycin and L-glutamine (Gibco), supplemented
with 15% heat inactivated fetal bovine serum (Gemini Bio-
Products, West Sacramento, CA, USA). Collagenase digestion
media consisted of collagenase type II (Sigma-Aldrich C6885, St.
Louis, MO, USA) dissolved at 1 mg/mL (693 collagen units or 2.8
FALGPA units per mL) in a 1:1 mixture of PBS and R15, based
on a titration in which we determined 700 collagen units/mL to be
optimal. All sites used the same lot of collagenase (091M8608V).
Collagenase digestion media was warmed for 30 minutes in a
37uC water bath before use. On receipt in the lab, biopsies were
washed with 10 mL PBS and in some instances, to facilitate
digestion, cut into smaller pieces with sterile razor blades. Samples
were then placed into an 8 mL round-bottom tube (BD)
containing 3 mL collagenase digestion media, with 1 unit/mL
DNase 1 (Sigma) to prevent cell clumping. The tubes were shaken
at 200 rpm in a 37uC incubator for 30 minutes. The collagenase
digestion media and biopsies were then aspirated into and expelled
from a 3 mL syringe through a blunt 16 gauge needle ten times
and the cell suspension passed through a 70 mm cell strainer into
fresh R15. The tube, syringe, and strainer were then washed with
R15, which was added to the cell suspension. The tissue collected
on the strainer was placed in fresh collagenase digestion media
with DNase and shaken for another 30 minutes. This cycle was
repeated up to four times. Any material left after the fourth
digestion was discarded. During subsequent rounds of digestion,
the cell suspension was centrifuged and cell pellets were
resuspended in R15 and kept on ice. The full collagenase digestion
protocol is included in File S3.
Leukocyte isolation by emigration
Biopsies were washed five times with cold PBS in a 15 mL tube,
placed in RPMI-1640 in a well of a six-well plate, and cut into
small pieces with sterile razor blades. Cold PBS was added
vigorously and then the supernatant removed carefully ten times to
wash away loose epithelial cells and decrease the chance of
bacterial or fungal contamination. After the tenth wash, 5 mL R10
(RPMI-1640, penicillin-streptomycin and L-glutamine (Gibco),
supplemented with 10% heat inactivated fetal bovine serum) was
very gently added and the biopsies cultured in a 37uC incubator
with 5% CO2 for 48 hours. After incubation, collagenase D
(Applied Science, Indianapolis, IN, USA) was added drop-wise to
the wells for a final concentration of 2 mg/mL and incubated for
10 minutes at 37uC. The supernatant containing the cells was then
carefully removed without disturbing the tissue. The biopsies were
washed very gently with media and the media combined with the
cell suspension.
Leukocyte isolation by enzyme cocktail
Biopsies were digested as in the collagenase protocol, with the
following modifications. The same collagenase was used at the
same concentration, with the addition of Elastase at 0.07 U/mL
(Worthington Biochemicals Lakewood, NJ, USA), Hyaluronidase
at 0.4 U/mL (Worthington), and DNase I 0.083 U/mL (New
England Biolabs, Ipswich, MA, USA). The enzymes were
dissolved in R7.5 (RPMI-1640, penicillin-streptomycin and L-
glutamine (Gibco), supplemented with 7.5% heat inactivated fetal
bovine serum) rather than a mixture of R15 and PBS. Biopsies
were vortexed in digestion media for 1 min and then shaken for
30 minutes. After shaking, the cells were passed through a strainer
and the tissue pieces broken up with a 200 mL pipet tip. Biopsies
were then returned to the shaker in fresh digestion media.
Digestions were repeated a total of up to three times.
Staining and flow cytometry acquisition
Cells suspended in PBS were transferred to 5 mL round-
bottom, snap cap tubes (BD) and stained with the LIVE/DEAD
Fixable Aqua Dead Cell Stain kit (Life Technologies, Grand
Island, NY, USA) in PBS. Cells were washed with FACS wash
(PBS containing 1% bovine serum albumin [Sigma]) and stained
with the antibody panel for phenotyping (Table S1). Cells were
washed again with FACS wash, resuspended in 250 mL 1%
paraformaldehyde, and transferred to Trucount Absolute Count-
ing Tubes (BD). The staining tubes were washed with an
additional 250 mL 1% paraformaldehyde, which was then added
to the Trucount tubes. In Seattle and Nairobi, cells were stained in
v-bottom, 96-well plates for Part 1; all sites used tubes in Part 2.
In Part 2, after the viability stain, cells were stained with Act-1
[17], washed and stained with biotinylated goat anti-mouse
antibody (Beckman Coulter, Brea, CA, USA), washed twice and
stained with the phenotyping panel plus streptavidin PE-Cy5 (BD).
Antibody panel optimization and titrations were performed in
peripheral blood mononuclear cells, followed by confirmation
using cells isolated from cytobrushes. The Act1 reagents were
titrated using digested vaginal tissue obtained from vaginal repair
surgeries.
Compensation controls were prepared simultaneously with
sample processing, using CompBead Plus (BD) for antibodies
and ArC Amine Reactive Compensation Beads (Life Technolo-
gies) for the viability stain. Samples were acquired on LSRII flow
cytometers (BD), equipped with 405 nm, 488 nm, and 635 nm
lasers at all sites, with the addition of a 535 nm laser in Seattle.
Forward and side scatter voltages were normalized using Trucount
beads and fluorescence parameter PMTs were normalized by use
of Rainbow Calibration Particles, Peak 7 (Spherotech, Lake
Forest, IL, USA).
Data analysis
Standardization of procedures and assays enabled data pooling
and comparison between laboratories at multiple sites. FACS data
files were transferred to the Seattle site for centralized analysis,
which was done by co-author SMH using FlowJo 9.6 for Mac
(Tree Star, Ashland, OR, USA), Excel 2010 for Windows
(Microsoft, Redmond, WA, USA), and Prism 5.01 for Windows
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(GraphPad Software, La Jolla, CA, USA). The gating scheme is
shown in Figure S1. Absolute cell numbers were determined by
measuring the number of Trucount beads acquired and dividing
this number by the known total number of beads in the tube, thus
determining the fraction of the sample acquired. From there, the
number of cells acquired was divided by the fraction of the sample
acquired to calculate the total number of cells present in the
sample.
The a4b7 analysis only included samples where at least 50 cells
of a given subset were recovered. The positive staining gate was set
by using the CD45neg cell population, which we had determined in
preliminary experiments to match FMO controls, as an internal
negative control. The general cut-off for a4b7 positivity was set at
the threshold of 99.5% of CD45neg cells staining a4b7 negative.
Due to non-specific binding of the streptavidin PE-Cy5 reagent to
macrophages, no information about a4b7 expression on these cells
could be determined.
Statistical analyses
Sample sizes were calculated to detect differences between the three sample
types in the primary outcome measurement of total mononuclear leukocyte yields
within each study site. Wilcoxon signed rank tests were used to
compare two different sample types from the same participants
(Parts 1 and 2) and to compare the same sample types from
participants collected at different time points. Inter-site variations
of cell numbers and frequencies were tested using unpaired
Kruskal Wallis ANOVA (with Dunn’s multiple comparison
adjustment). Mann Whitney tests were used to compare the effect
of visible red blood cells, and of DMPA use, on cell yields. All tests
were two-tailed at a= 0.05. Pearson correlations were used to
analyze the linear association between cytobrush sampling at two
different visits and between duplicate biopsies.
Results
Participant characteristics
This study was conducted in two parts and enrolled women
from four study sites. The participants were HIV-uninfected
healthy women between the ages of 18 and 37. In Part 1 of the
study (comparison of CVL and cervical cytobrush), we enrolled 16
women each from Chicago (median age 25, IQR 24–29), Nairobi
(31, 27–34) and Seattle (32, 27–37) for CVL and endocervical
cytobrush sampling. In Part 2 (comparison of cervical cytobrush
and cervical biopsy), we enrolled 17 women from Chicago (27, 23–
30) and Nairobi (25, 23–27), and 20 from Seattle (30, 27–36), for
cytobrush and cervical biopsy sampling. In addition, we enrolled
25 women from Cape Town for cytobrush sampling only (median
age 31, IQR 26–33). Five additional women tested positive for an
STI in the screening phase and were therefore not enrolled. One
additional Seattle participant was excluded because the biopsy was
not kept on ice and one additional Chicago participant was
excluded for amenorrhea.
Part 1: Comparison of endocervical cytobrushes and
cervicovaginal lavages
In Part 1, carried out in Chicago, Nairobi and Seattle, we
compared the yield and composition of leukocytes obtained from
two sequential endocervical cytobrushes to one 10 mL CVL from
each participant. Subpopulations of CD45+ leukocytes were
phenotyped using a pre-defined gating strategy (Figure S1), and
the absolute number of viable cells per sample was calculated using
the fraction of absolute counting beads acquired. Cytobrush
sampling yielded more viable leukocytes than CVL (Figures 1A
and B). The median number of viable CD45+ leukocytes from two
sequential cytobrushes was 5,810 (IQR 2,075–17,656) across all
sites, while CVL samples yielded a median of 1,667 CD45+ cells
(IQR 321–4,185; p,0.0001). The higher CD45+ cell yield from
cytobrushes was observed at all sites (p,0.05 in Chicago and
Nairobi; p = 0.11 in Seattle). Of note, only a minority of all cells
obtained by either method expressed CD45, with the percentage
of CD45+ cells significantly higher in cytobrush versus CVL
(cytobrush median 0.81%, IQR 0.27–1.7; CVL median 0.09%,
IQR 0.03–0.24; p,0.0001). The viability of CD45+ leukocytes
was similar between the two sample methods (cytobrush median
68.9%, IQR 56.3–82.9; CVL median 67.1%, IQR 36.6–93.5;
p = 0.6779).
Consistent with larger overall CD45+ populations, cytobrushes
yielded significantly more CD4+ and CD8+ T cells, CD14+
macrophages, CD19+ B cells, and CD19neg HLA-DQ+ DCs than
CVLs (Figure 1B and Table 1). Macrophages/monocytes were the
largest subpopulation in both sample types (medians of 2,233 for
cytobrush and 266 for CVL; p = 0.0001). T cells were the second
largest population (medians 1,170 and 89 for CD4+; 815 and 44
for CD8+; both p,0.0001). B cells and dendritic cells (DC) were
much less frequent (medians of 236 and 59 for B cells; p = 0.044;
83 and 11 for DCs; p,0.0001). Statistical significance was not
always observed when the analysis was repeated on individual site
level data, but the directions of the trends remained the same.
In addition to absolute numbers, we evaluated the percentage of
the CD45+ compartment constituted by each subpopulation
(Figure 1C). T lymphocytes were relatively enriched in cytobrush
compared to CVL (median 20.4 vs. 6.8% for CD4; 15.8 vs. 3.9%
for CD8; p,0.0001 for both T cell subsets), whereas the reverse
was seen for B cells (3.5 vs. 7.6%; p = 0.0017). No differences were
observed in the percentages of macrophages or DCs between
cytobrush and CVL (35.6 vs. 34.2% for macrophages; 2.1 vs. 2.0%
for DCs; p = 0.8335 and p = 0.7779, respectively). Cytobrushes
contained a substantially lower fraction of CD45+ cells than CVL
that could not be defined as one of the five immune subpopula-
tions (median 14.5 vs. 27.5%; p = 0.0005; Figure 1C).
In summary, two sequential cytobrushes give substantially
greater numbers of all leukocyte populations tested than CVL
samples. We therefore chose cytobrush sampling as the better of
the two non-invasive methods to compare to biopsy sampling in
Part 2 of the study.
Part 2: Comparison of endocervical cytobrushes and
ectocervical biopsies
Mucosal biopsies are traditionally believed to be the ‘‘gold
standard’’ for obtaining the highest cell yields. However, biopsy
sampling is invasive and we were therefore interested to
systematically evaluate whether comparatively non-invasive cyto-
brush sampling yields equivalent viable cell numbers and
distributions of leukocyte subpopulations.
As a preparatory step for Part 2, we first determined the optimal
method for leukocyte isolation from cervical tissue. We compared
three methods using equally sized biopsies taken from vaginal
tissue obtained from several patients undergoing vaginal repair
surgeries. Collagenase plus DNase digestion yielded substantially
greater numbers of CD45+ leukocytes (median 119,248) than
either a cocktail of four enzymes (median 25,136) or emigration
(median 21,588) (p,0.05; Figure S2A). Cells obtained by
emigration were proportionally enriched for CD45 expression,
although overall numbers were lower, and the cells obtained by
this method were almost exclusively T cells. T cells were also the
dominant leukocyte population isolated by collagenase or enzyme
cocktail digestion, but both enzyme digestion procedures gave
substantial frequencies of CD14+ macrophages, few of which were
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seen in the emigration protocol (Figure S2B). Due to the
substantially larger CD45+ yield from the collagenase digestion
protocol, this procedure was chosen for the formal comparison
with cytobrushes in Part 2. All three participating sites (Chicago,
Nairobi and Seattle) used the same lot and concentration (1 mg/
mL or 693 collagen units/mL) of collagenase, which we
determined to be optimal for cell yield without reducing
expression of surface antigens (Figures S2C and D).
We then proceeded to Part 2 of our study, carried out in
Chicago, Nairobi and Seattle. We found that two sequential,
combined Digene cytobrushes yielded comparable numbers of
CD45+ leukocytes as one 4.262.3 mm bite size biopsy (cytobrush
median 11,008, IQR 2,396–36,873; biopsy median 9,717, IQR
4,092–25,535; p = 0.53) (Figures 2A and B, Table 2). Viable
CD45+ cells made up a smaller percentage of all cells in cytobrush
than in biopsies (cytobrush median 1.0%, IQR 0.43–2.6; biopsy
median 4.5%, IQR 0.97–11.3; p,0.0001), indicating that fewer
non-immune cells are present in biopsy-derived samples. This was
consistent across the sites (all p,0.05). Leukocytes from cyto-
brushes had slightly lower viability than from biopsies (median
76.1%, IQR 63.0–87.1 vs. 84.4%, IQR 70.0–89.9; p = 0.0010);
this was consistent in Nairobi and Seattle, but not observed in
Chicago (p = 0.7764).
Cytobrushes and biopsies differed considerably in the distribu-
tions of leukocyte subpopulations (Figure 2B and C). Cytobrushes
yielded notably fewer T cells than biopsies, with lower levels of
both CD4+ (median 2,043 vs. 3,979; p = 0.0044) and CD8+ T cells
(median 1,207 vs. 3,472; p,0.0001). Similarly, both T cell subsets
made up smaller fractions of CD45+ cells in cytobrushes than in
biopsies (median 15.7 vs. 36.3% for CD4; 8.1 vs. 35.8% for CD8;
both p,0.0001). Conversely, cytobrushes contained a higher
number and proportion of CD14+ cells compared to biopsies
(median 4,975 vs. 559; median 45.6 vs. 4.5% CD14+ cells; both
p,0.0001). Both sample types contained small numbers of B cells
and DCs, with cytobrushes having about twice the number of both
CD19+ B cells (298 vs. 146; p = 0.9143; 3.6 vs. 1.9%; p = 0.1409)
and DCs (171 vs. 82; p = 0.0835; 1.9 vs. 1.2%; p = 0.0004) when
compared to biopsies. CD45+ leukocytes isolated from cytobrushes
contained a modestly greater percentage of cells than biopsies that
could not be defined as one of the five immune subpopulations
(15.8 vs. 12.1%; p = 0.1409) (Figure 2C). Therefore, while no
overall difference in CD45+ cell recovery was observed between
sample types, there were significant differences in terms of
composition, with cytobrushes containing relatively more macro-
phages and biopsies more T cells.
Inter-site variation
To evaluate inter-site variation, we compared the recovery of
CD45+ leukocytes and each leukocyte subpopulation between the
Chicago, Nairobi and Seattle study sites (Figure 3). For CVL
samples, the main difference was that samples from Nairobi
contained significantly more CD45+ cells than those from Chicago
and Seattle (p,0.05 and p,0.01), which was possibly driven by
increased numbers in CD14+ cells (both p,0.05). Chicago and
Seattle CVLs also had proportionally fewer CD8+ T cells than
Nairobi (p,0.001 and p,0.01), and Chicago had proportionally
more DCs than Nairobi (p,0.05) (Figure 3A, left).
Cytobrush samples were remarkably consistent across sites,
especially in Part 2, where all sites were more experienced and
used the same device. In Part 2, there were no statistically
significant differences in the total number of CD45+ cells or
leukocyte subpopulations between the sites, but there were some
differences in the frequencies of certain subpopulations (Figure 3A,
center). The percentages of CD4+ and CD8+ T cells were higher in
Figure 1. Comparison of immune cell yield and distribution in
endocervical cytobrush (CB) and cervicovaginal lavage (CVL)
samples. (A) Representative gates for identification of CD45+
leukocytes from cytobrush and CVL samples. (B) Numbers of CD45+
leukocytes, CD4+ T cells, CD8+ T cells, CD19+ B cells, CD14+
macrophages, and CD19neg/HLA-DQ+ DC enumerated from cytobrush
and CVL samples. Cell numbers were log10 transformed, and plotted per
site (Chicago, red dots; Nairobi, blue dots; Seattle, black dots).
Horizontal bars indicate median values for each site. (C) Percentage
contribution of each cell subset, as well as of cells that do not fit one of
the described populations (‘‘unknown’’), to the total CD45+ population
from cytobrush and CVL samples. Data are averaged across sites. P
values are listed in the text, and median and IQR in Table 1.
doi:10.1371/journal.pone.0085675.g001
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Seattle than in Nairobi (both p,0.01). Samples from both Nairobi
and Chicago contained larger percentages of dendritic cells than
those from Seattle (p,0.01 and p,0.05).
Biopsy samples were also relatively consistent across sites
(Figure 3A, right). Some minor differences were noted, specifically
in the number of DCs (Nairobi having more than Seattle; p,0.05),
the number of B cells (Chicago having more than Nairobi;
p,0.01), the number and percentage of CD14+ cells (Nairobi
having more than Chicago; p,0.001 and p,0.01), and the
percentage of CD4+ T cells (Seattle and Chicago having more
than Nairobi; p,0.05).
In summary, site-to-site variations in total CD45+ cell yields and
leukocyte subpopulation distributions were minor, in particular for
endocervical cytobrush and ectocervical biopsy specimens. Our
study therefore demonstrates that cervical cytobrush and biopsy
sampling, and the immunophenotyping of the isolated cell
populations, can be performed in a standardized manner across
several study sites.
Reproducibility of cytobrush and biopsy sampling
To assess the reproducibility of cytobrush sampling, we
compared the consistency of isolated immune cells from
cytobrushes taken from the same participants at different times.
These data were available from the Chicago site, where 12 women
were sampled for both Part 1 and Part 2 of the study, with a
median of 530 days between visits (IQR 503–566). Median CD45+
leukocyte yields across all women in Chicago were similar between
Part 1 (n = 16) and Part 2 (n = 17) (12,956, IQR 6,502–29,177 vs.
15,275, IQR 4,122–38,749; p = 0.9587) (Figure 3B). Among the
12 women sampled twice, there was weak evidence of a positive
correlation in CD45+ cell yields between Part 1 and Part 2
(r = 0.49, p = 0.1063) (Figure 3C). However, some of these 12
women showed differences of up to 10-fold between the two time
points (paired samples in Figure 3B). These data suggest that
cytobrush sampling yields consistent results over time when judged
at the cohort level, but that individual women may exhibit
substantial fluctuations.
To assess the reproducibility of cervical biopsies, two simulta-
neous biopsies were taken from 7 participants from the Nairobi
site from the upper left and right quadrants of the ectocervix.
Numbers of CD45+ leukocytes were strongly correlated between
duplicate biopsies from the same participant-visit (r = 0.89,
p = 0.0123; Figure 3D), as were the numbers of CD4+ T cells
(r = 0.86, p = 0.0238), CD8+ T cells (r = 0.96, p = 0.0028), and
DCs (r = 0.89, p = 0.0123; not shown). However, there were no
significant correlations between numbers of CD14+ macrophages
(r = 0.57, p = 0.2) or CD19+ B cells (r = 0.44, p = 0.36; not shown).
Occasionally, for some subpopulations, we observed large
differences between duplicate biopsies. For example, in one
participant, recovery of B cells was 5,777 in biopsy A compared
to 264 in biopsy B; CD4+ T cell recovery was similarly skewed,
with 14,738 in biopsy A compared to 2,424 in biopsy B. Thus,
overall leukocyte yields correlated between two ectocervical
biopsies taken on the same day, but individual subpopulations
sometimes differed markedly.
Impact of blood contamination on leukocyte yields from
cytobrushes
Cytobrush sampling is associated with occasional blood
contamination, particularly with a second consecutive brush. At
the time of sampling, clinicians recorded any visible red blood cell
contamination. Using this information, we compared the cell
populations obtained from cytobrushes in the absence or presence
of blood. CD45+ cell yield from cytobrushes with blood was
significantly higher than from cytobrushes without blood (median
16,760 vs. 4,603; p = 0.0078; Figure S3A). While cytobrushes with
blood contamination yielded greater numbers of leukocytes,
CD45+ cells made up a smaller fraction of all cells in those
samples (median 0.49 vs. 1.4%; p = 0.0315); this may be due to the
increased presence of red blood cells. There were no significant
differences in leukocyte subpopulation frequencies or viabilities in
the presence or absence of blood contamination (Figure S3B). The
median ratio of macrophages to T cells was 0.86 in samples with
visible blood and 1.05 in samples without blood (p = 0.6162).
Impact of depot medroxyprogesterone acetate (DMPA)
usage on leukocyte yields from cytobrushes
Cytobrush samples were also obtained from women at a site in
Cape Town (Figure S3C). These contained higher viable CD45+
cell yields (median 27,866, IQR 10,291–59,386) than the other
three sites for Part 2 (median 11,008, IQR 2,396–36,873;
p = 0.0265), where all four sites used the same device. Approxi-
mately two-thirds (68%) of women in Cape Town used injected
hormonal contraception with DMPA. In Nairobi and Chicago,
DMPA use was 0% and 9% (3/33), respectively (data not available
in Seattle). We hypothesized that DMPA use might explain the
higher leukocyte numbers in Cape Town, and therefore compared
the cell yields in Cape Town between participants on (n = 17) and
off DMPA (n = 8). Leukocyte yields were similar between these
groups (median 27,956 [IQR 11,683–52,380] versus 28,068 [IQR
9,040–68,190]; p = 0.9768) (Figure S3C). Thus, a preliminary
conclusion of these data is that DMPA use does not explain the
higher leukocyte numbers in Cape Town.
Table 1. Median (IQR) numbers of leukocyte subpopulations in endocervical cytobrushes (CB) and cervicovaginal lavages (CVL).
Chicago Nairobi Seattle
CB CVL CB CVL CB CVL
CD45+ 12,956 (6,502–29,177) 593 (144–2,347) 4,869 (3,261–32,486) 3,235 (2,449–6,386) 1,772 (869–7,037) 801 (76–2,809)
CD4 3,350 (1,563–8,108) 82 (13–222) 798 (299–4,288) 185 (29–553) 294 (202–1,204) 44 (7–356)
CD8 1,689 (700–4,399) 55 (10–153) 840 (194–2,339) 45 (0–101) 322 (162–781) 26 (0–225)
B 453 (76–1,700) 49 (20–138) 214 (56–704) 245 (40–1370) 111 (43–531) 33 (7–248)
MW 3,641 (1,611–13,081) 145 (25–558) 2,434 (1,490–8,660) 2201 (401–3,333) 541 (76–1,579) 187 (17–1187)
DC 545 (72–1,550) 21 (0–94) 59 (15–429) 13 (0–143) 25 (3–107) 11 (0–50)
CD4, helper T lymphocytes; CD8, cytotoxic T lymphocytes; B, B lymphocytes; MW, macrophages; DC, dendritic cells.
doi:10.1371/journal.pone.0085675.t001
Optimizing Genital Leukocyte Sampling
PLOS ONE | www.plosone.org 6 January 2014 | Volume 9 | Issue 1 | e85675
Impact of bacterial vaginosis on leukocyte yields from
cytobrushes and biopsies
Two participants (6%) from Chicago, four (27%, out of fifteen
for whom vaginal Gram stains were available) from Nairobi, and
10 (32%, out of 31 for whom vaginal Gram stains were available)
in Seattle, were diagnosed with BV. Eight out of 15 women
participating in Part 2 in Seattle and for whom vaginal Gram
stains were available had BV, enabling statistical analysis for this
subset of participants. Neither cytobrushes nor biopsies showed
differences in CD45+ leukocyte yields between women with or
without BV (cytobrushes: p = 0.6943; biopsies: p = 1) (data not
shown).
Expression of a4b7 on cervical cytobrush- and biopsy-
derived leukocytes
The integrin a4b7, involved in homing of leukocytes to the
mucosa, binds HIV-1 gp120 and previous reports have demon-
strated expression of this molecule on genital tract T cells [18–22].
Because of its hypothesized role in promoting HIV transmission
across the female genital tract [23,24], we were interested to
confirm its expression on cervical leukocytes and added an a4b7
stain to Part 2 of the study at the Chicago and Seattle sites. We
found a4b7 to be highly expressed on leukocytes isolated from
either cytobrushes or biopsies (Figure 4). Additionally, higher
frequencies of a4b7+ cells were observed in biopsy-derived cells
compared to cytobrush-derived cells for each subpopulation
examined, including CD4+ T cells (median 70.9% for biopsy vs.
45.6% for cytobrush; p,0.0001), CD8+ T cells (median 95.4 vs.
81.3%; p,0.0001), DCs (median 84.5 vs. 72.9%; p = 0.0840), and
B cells (median 80.8 vs. 55.1%; p = 0.0012). These data
demonstrate high a4b7 expression on leukocytes derived from
both the endocervix (cytobrushes) and ectocervix (biopsies).
Discussion
Cellular immune responses are thought to constitute an integral
part of the protective responses elicited by candidate HIV
vaccines, and therefore we urgently need to better understand
these at the mucosa, where HIV exposure occurs [25]. The
analysis of cellular immunity requires live, functional cells, and
therefore remains more challenging than measuring soluble
antibodies and innate immune factors in mucosal secretions. Live
mucosal cells are also required to evaluate the pharmacodynamics
(cellular resistance to HIV infection) and pharmacokinetics
(intracellular active drug concentrations) of candidate anti-HIV
microbicides [11]. It is therefore imperative to determine the best
sampling procedures to obtain viable cells from the mucosa, and
optimize standardized processing and analysis protocols. This will
serve to maximize achievable viable cell yields and reduce
sampling variability, allowing better discrimination of biological
from methodological variation [26,27] and more reliable inter-site
comparisons.
Here, we compared three common genital cell sampling
methods, at two research sites in the USA and one in Nairobi,
Kenya, using standardized clinical sampling, specimen processing
and flow cytometric analysis procedures. Our data show that two
sequential, combined endocervical cytobrushes and one ectocervi-
cal biopsy yielded a median of approximately 10,000 viable
CD45+ leukocytes each, with the major difference lying in the
relative distribution of T cells and macrophages: biopsies
contained more T cells and cytobrushes more macrophages.
CVL specimens consistently provide much smaller cell yields than
either cytobrushes or biopsies, and are therefore not suitable for
cellular analyses. Of note, in all sample types, CD45+ mononu-
Figure 2. Comparison of immune cell yield and distribution in
endocervical cytobrush (CB) and ectocervical biopsy samples.
(A) Representative gates for identification of CD45+ leukocytes from
cytobrush and biopsy samples. (B) Numbers of CD45+ leukocytes, CD4+
T cells, CD8+ T cells, CD19+ B cells, CD14+ macrophages, and CD19neg/
HLA-DQ+ DC enumerated from cytobrush and biopsy samples. Cell
numbers were log10 transformed, and plotted per site (Chicago, red
dots; Nairobi, blue dots; Seattle, black dots). Horizontal bars indicate
median values for each site. (C) Percentage contribution of each cell
subset, as well as of cells that do not fit one of the described
populations (‘‘unknown’’), to the total CD45+ population from cyto-
brush and biopsy samples. Data are averaged across sites. P values are
listed in the text, and median and IQR in Table 2.
doi:10.1371/journal.pone.0085675.g002
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clear leukocytes constituted a small minority of all cells. Most other
cells were likely epithelial cells, but recently we also identified a
population of neutrophilic granulocytes in cytobrushes (unpub-
lished), which express intermediate levels of CD45 and thus were
mostly excluded from our analyses, where gating was specific to
CD45high cells (Figures 1 and 2, Figure S1). Two previous studies
also reported that neutrophils accounted for about 50% of the
leukocytes in cervical cytobrushes and 10–15% in cells isolated
from cervical and vaginal biopsies [28,29].
While this result suggests that the use of biopsies is better for
evaluating antigen-specific T cell responses, biopsies come with the
perceived or real disadvantages of increased risk of bleeding and
infection, including with HIV, as a result of the disrupted epithelial
barrier [30]. In this context, the cytobrushes taken more than one
year apart from the same women in Chicago, in the same stage of
the menstrual cycle, are interesting. At the cohort level, cell yields
and subpopulation distributions were consistent from one time
point to the next, which validated the standardized procedures
employed. However, in individual women, cell yields could vary
up to tenfold between visits. This indicates that repeated cytobrush
sampling increases the likelihood of obtaining at least one sample
with a high cell yield. Since repeated cytobrush sampling is quite
feasible, more frequent cytobrush sampling, and possibly pooling
of cells from different clinic visits, could be a good alternative to
more invasive biopsy sampling. However, for pooling to be
feasible, effective cryopreservation of cytobrush cells is necessary.
The Seattle authors of this paper are currently conducting
systematic cryobiological studies of mucosal samples. We antici-
Table 2. Median (IQR) numbers of leukocyte subpopulations in endocervical cytobrushes (CB) and ectocervical biopsies.
Chicago Nairobi Seattle
CB Biopsy CB Biopsy CB Biopsy
CD45+ 15,893 (4,018–39,742) 5,345 (3,467–22,357) 12,942 (1,930–48,080) 28,645 (5,754–73,043) 8,396 (2,471–24,604) 9,369 (4,935–23,644)
CD4 2,797 (515–4,407) 2,422 (721–9,287) 672 (161–5,496) 5,117 (659–27,530) 2,014 (649–4,687) 4,341 (2,006–7,623)
CD8 1,229 (418–2,404) 2,310 (949–9,608) 387 (93–2,820) 4,753 (2,050–31,614) 1,099 (300–2,204) 3,303 (1,835–8,327)
B 485 (112–801) 53 (24–492) 317 (107–1,478) 571 (196–3,738) 261 (77–543) 92 (39–701)
MW 7,380 (1,193–27,016) 98 (44–845) 10,814 (875–23,052) 1,683 (913–4,206) 2,445 (616–15,326) 392 (300–1,550)
DC 405 (123–842) 81 (35–386) 495 (44–2,625) 234 (77–916) 37 (8–337) 63 (17–111)
CD4, helper T lymphocytes; CD8, cytotoxic T lymphocytes; B, B lymphocytes; MW, macrophages; DC, dendritic cells.
doi:10.1371/journal.pone.0085675.t002
Figure 3. Inter-site variability and sample reproducibility from
female genital tract immune cell sampling techniques. (A)
Percentage contribution of each immune cell population to the total
CD45+ population recovered from CVL, cytobrush, and biopsy samples
collected at the Seattle, Chicago, and Nairobi study sites. (B) Numbers
of CD45+ leukocytes recovered from cytobrush samples collected from
all women recruited in Chicago. Filled circles and connecting lines
indicate women participating in both Part 1 and Part 2 of the study
(n = 12). Open circles indicate women sampled only in one part of the
study. Boxes indicate median, interquartile range and total range. (C)
Scatterplot of cell numbers from the twelve women sampled in both
Part 1 (x axis) and Part 2 (y axis) of the study. (D) Scatterplot of cell
numbers from replicate biopsies collected at the same clinic visit in
seven participants at the Nairobi study site. Biopsies were taken from
upper left and upper right quadrants of the ectocervix.
doi:10.1371/journal.pone.0085675.g003
Figure 4. Percentages of a4b7+ immune cells isolated from
cytobrush (CB) and biopsy samples at the Seattle (black dots)
and Chicago (red dots) study sites. Percent a4b7 expression on
CD4+ T cells, CD8+ T cells, CD19+ B cells and CD19neg/HLA-DQ+ DC.
Samples are only shown if more than 50 cells were acquired for the
indicated population. Horizontal bars indicate median values for each
site.
doi:10.1371/journal.pone.0085675.g004
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pate that improved cryopreservation techniques will soon provide
more flexibility in analyzing mucosal samples, allowing shipping,
banking and pooling of viable mucosal cells. Importantly, this will
alleviate the need for high tech laboratories in the vicinity of each
trial site, which is a major limiting factor for analyzing cellular
mucosal immune responses in clinical trials.
Though cytobrushes and biopsies provide similar numbers of
cells, it is notable that they are derived from two different
microanatomical sites. Cytobrush sampling is performed from the
endocervical canal and thus the cells are presumably derived from
the transformation zone, as well as from within and beneath the
columnar epithelium of the endocervix. In contrast, unless the
cervix has an extensive cervical ectopy, as can occur in younger
women [31], the biopsy cells will be derived from the squamous
epithelium and stroma of the ectocervix. Functional differences
may exist between endocervical and ectocervical leukocytes,
including relative frequencies of memory and effector subsets.
Whole endo- and ectocervical tissue certainly appears to contain
some immunologic compartmentalization when assessed by
proteomic analyses, which may impact HIV susceptibility [32].
While these differences need to be studied in more detail, it is
encouraging that viable T cells and antigen-presenting cells
(macrophages and DCs) can be isolated from both endocervical
cytobrushes and ectocervical biopsies, likely allowing the determi-
nation of vaccine-induced cellular immune responses with either
sample type. Another sample type from the female genital tract is
menstrual blood, which has the advantage that it can be self-
obtained by women who are instructed in the use of menstrual
collection cups [33]. Mucosal cells in menstrual blood are likely
derived mostly from the endometrium – it will be interesting to
compare their phenotypes and function to those collected with
cytobrushes or biopsies.
Consistency of sampling and analysis methods across study sites
is crucial for clinical trials. Yields of viable CD45+ leukocytes were
remarkably consistent across samples from Nairobi, Chicago and
Seattle, the three sites that took part in all aspects of the study.
This was particularly true for cytobrushes and biopsies in Part 2,
where standardization of sampling devices and processing was
rigorously implemented (cytobrush cell yields were generally lower
in Part 1 than in Part 2, likely owing to some Part 1-specific issues
regarding technician skill in Seattle as well as lack of sample device
standardization in Part 1). The fact that the overall leukocyte
yields aligned so well at the three sites validates our standardiza-
tion efforts and demonstrates the feasibility of performing cellular
mucosal assays in multi-site trials. It also suggests that the few
differences we saw in leukocyte subpopulation distribution
between sites could be driven not by methodological divergences
but reflect true differences in sample composition. Likewise,
CD45+ leukocyte yields from biopsies taken in the same procedure
from two different ectocervical locations were highly correlated,
but subpopulation composition sometimes varied, presumably due
to regional differences between the particular tissue pieces
sampled. Thus, a range of biological variables needs to be
contended with when analyzing mucosal samples, which under-
scores the necessity for adequate sample sizes in mucosal studies.
The potential for variability in sample composition from
different cohorts is underscored by our finding that cytobrushes
from women in Cape Town yielded a median of 2.5 times the
number of CD45+ leukocytes than cytobrushes from Part 2 at the
other three sites. Neither blood contamination nor higher DMPA
use explains this difference. It is notable by itself, though, that
women using DMPA did not exhibit higher leukocyte numbers in
their cytobrush samples. One of the hypotheses put forward to
explain reported epidemiological evidence that women on DMPA
experience higher HIV susceptibility posits that DMPA leads to
higher concentrations of HIV target cells in the genital mucosa
[34,35]. Our findings suggest that DMPA use does not increase the
number of HIV target cells captured by endocervical cytobrushes.
However, the number of women in this particular sub-study was
small, since it was only conducted at the Cape Town site, and it is
unknown how sensitively alterations of cell densities in situ
translate to changes in cytobrush specimens.
One of the questions repeatedly raised with mucosal samples is
to what extent they are contaminated with peripheral blood. We
therefore systematically analyzed cytobrushes for the impact of
visible red blood cells on leukocyte yields and subpopulation
distribution. We found that visibility of red blood cells increased
median leukocyte yields approximately 3.6-fold, but it did not
dramatically change the composition of subpopulations. The
median ratio of macrophages to T cells in samples with visible
blood (0.86) was comparable to samples without blood (1.05). This
is in contrast to the distribution of monocytes and T lymphocytes
in peripheral blood, where the average ratio of monocytes to T
cells is 0.25. If visible red blood cells in cytobrushes signified
substantial contamination with peripheral blood, this should have
driven the ratio of monocytes/macrophages to T cells much more
strongly toward the ratio generally found in peripheral blood.
Thus, visible red blood cells in cytobrushes did not signify
substantial contamination with peripheral blood cells, a conclusion
that is supported by a previous paired comparison of blood and
cytobrush cell phenotypes [28]. Rather, visible red blood cells, and
concomitant leukocytes, are likely derived from local microvessels,
which are actively involved in attracting leukocytes to the mucosa
via specific adhesion molecules and chemokine gradients, and thus
form part of the mucosa-specific environment. The same
assumption applies to cervical biopsies, where visible red blood
cells are nearly always observed.
The a4b7 integrin has recently been identified as an HIV
binding receptor with possible pathogenetic relevance in the
mucosa [18–22]. Approximately half of cytobrush and two thirds
of biopsy CD4+ T cells expressed a4b7 in our study (overall range
5 to 95%), which supports the potential importance of this
molecule for HIV pathogenesis. Percentages of a4b7+ cells were
even higher among CD8+ T cells, B cells and DCs (macrophages
could not be evaluated), but the relevance of a4b7 for HIV
susceptibility is less clear for these cell types. That the a4b7
frequencies were generally higher than in past studies is likely due
to the increased sensitivity achieved through amplification of Act-1
staining with two secondary reagents. Act-1 has been reported as
highly specific for the a4b7 dimer [17,22] and we performed
rigorous specificity experiments for all reagents before including
a4b7 staining in Part 2 of our study. Nevertheless, for the actual
samples we relied on an internal negative control rather than a
separate isotype control or FMO, because the study was designed
to avoid splitting of samples. Thus, some uncertainty remains as to
the precision of our measured frequencies, but in principle our
data confirm prior publications [18,21]. Of note, cells derived
from the ectocervix expressed higher levels of a4b7 than cells from
the endocervix. However, it is possible that the tissue digestion
procedure might have led to up-regulation of this receptor, or that
its expression decreases when cells are released from the
endocervix into the endocervical canal.
In summary, we have carried out the most comprehensive study
comparing cervical cell sampling methods to date, using a multi-
site design to reflect the needs of global clinical trials. In addition
to our data on the relative merits of cytobrushes, biopsies, and
CVL, we have also provided standardized methodologies that can
be used to set up multi-site studies of mucosal immunology. We
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have established ranges of absolute cell numbers and frequencies
for each subpopulation tested. These can inform sampling
decisions during HIV clinical trials. They also emphasize that
even with optimal sampling and specimen processing procedures
studies of genital immunity are hampered by the relatively low cell
numbers available. Single cell analysis technologies, which are
currently being developed with promising speed, offer the best
prospect of overcoming this basic limitation [36,37].
Supporting Information
Figure S1 Representative flow cytometry gating strate-
gy for enumeration of leukocyte subpopulations. (A)
Forward/side scatter of endocervical cytobrush cells with depic-
tion of Trucount bead (small box) and cell (large box) gates. (B)
Gate used for Trucount bead enumeration. Beads gated in (A)
were depicted in APC and FITC fluorescence, gated and counted.
(C) For cell analysis, any contaminating Trucount beads were
excluded using a ‘NOT’ gate. (D) Cells are defined as leukocytes
by CD45 expression. (E) Viability is defined by exclusion of dead
cells using the LIVE/DEAD Fixable Aqua Dead Cell Stain. (F–H)
Identification of subpopulations of CD45+ viable leukocytes. (F)
Macrophages are defined by CD14 expression and T cells by CD3
expression. (G) Cells defined as CD3+ lymphocytes in (F) are
delineated into CD4+ and CD8+ T cells. (H) Cells gated as
CD14neg and CD3neg in (F) are defined as CD19+ B cells,
CD19neg/HLA-DQ+ dendritic cells, and ‘‘unknown’’ cells (lower
left quadrant).
(TIF)
Figure S2 Optimization of immune cell recovery from
vaginal tissue for use on ectocervical biopsy in Part 2 of
the study. (A) Numbers of CD45+ cells isolated from paired
samples by collagenase or enzyme cocktail digestion, or by
emigration. Procedures were performed in parallel on tissue from
two donors, with three replicates per procedure per donor. (B)
Percent of recovered CD3+ (black) and CD14+ (gray) cells out of
all CD45+ leukocytes from different procedures. (C) Comparison
of cell numbers obtained following collagenase digestion using
collagenase from Sigma (blue) and Gibco (red) in three donors. (D)
CD4 ECD staining intensities of vaginal CD3+CD8neg T cells after
digestion of biopsies with varying concentrations of collagenase,
ranging from 0.5 to 5 mg/mL (347–3470 collagen units/mL).
Horizontal bars indicate medians.
(TIF)
Figure S3 Influence of red blood cell contamination or
DMPA use on immune cell yield following cytobrush
sampling. (A) Numbers of CD45+ leukocytes for cytobrush
samples with or without visible red blood cells, collected at Cape
Town (green), Chicago (red), Nairobi (blue), and Seattle (black).
(B) Percentage contribution of each immune cell subpopulation to
the total CD45+ population recovered from cytobrush samples
with or without visible red blood cells. In (A–B), CBs from Part 2
at the Nairobi site and from women not on DMPA in Cape Town
are excluded because the presence of blood contamination was not
recorded. (C) Numbers of CD45+ leukocytes are shown for
cytobrush samples from women with or without DMPA use. Only
data from the Cape Town site, where many study participants
used DMPA, are shown. Horizontal bars indicate medians.
(TIF)
File S1 The full CVL processing protocol.
(PDF)
File S2 The full cytobrush processing protocol.
(PDF)
File S3 The full collagenase digestion protocol.
(PDF)
Table S1 Antibody panel for Mucosal cell phenotyping.
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